This study is carried out to assess the cardiopreventive effect of (E)-N’-(1-(7-methoxy-2-oxo-2H-chromen-3-yl) ethylidene)-4-methylbenzenesulfonohydrazide or SHC, a novel synthesized coumarin, against myocardial infarction induced by isoproterenol (ISO). The SHC compound was identified and characterized by spectral methods (infrared, ¹H NMR [nuclear magnetic resonance], ¹³C NMR, Nuclear Overhauser Effect Spectroscopy, and high-resolution mass spectroscopy). Male Wistar rats were divided into four groups: Control, ISO (rats were injected subcutaneously by 85 mg/kg body weight [BW] of isoproterenol at Days 6 and 7 of the experience), ISO + SHC (150 µg/kg BW, orally for 7 days) and ISO + acenocoumarol (150 µg/kg BW, orally for 7 days). Results showed that ISO induced a remarkable alteration of electrocardiogram (ECG) pattern and increases of plasma cardiac troponin T, creatine kinase-MB, total cholesterol, triglycerides, low-density lipoprotein-cholesterol, lactate dehydrogenase, aspartate transaminase, and malondialdehyde. In addition, ISO reduced the high-density lipoprotein-cholesterol content and the activities of superoxide dismutase and glutathione peroxidase, with the induction of myocardial necrosis. However, SHC administration revealed a significant decrease in cardiac dysfunction markers, restored normal ECG pattern, as well as improving lipids parameters. Moreover, SHC treatment remarkably alleviated the cardiac oxidative stress and the myocardial remodeling process. Overall, the SHC offers good protection from acute myocardial infarction through the antioxidant capacity.

中文翻译：

---

新型 (E)-Nʹ-(1-(7-methoxy-2-oxo-2H-chromen-3-yl) 亚乙基)-4-甲基苯磺酰肼通过调节生化、氧化应激对异丙肾上腺素诱导的心肌梗塞的心脏预防能力，和组织学参数

本研究旨在评估 (E)-N'-(1-(7-methoxy-2-oxo-2H-chromen-3-yl) 亚乙基)-4-甲基苯磺酰肼或 SHC 的心脏预防作用，这是一种新型合成的香豆素，对抗异丙肾上腺素 (ISO) 诱发的心肌梗塞。通过光谱方法（红外、¹ H NMR [核磁共振]、¹³ C NMR、核奥弗豪瑟效应光谱和高分辨率质谱）鉴定和表征了 SHC 化合物。男威斯塔大鼠分为四组：对照组、ISO（在实验的第 6 天和第 7 天，大鼠皮下注射 85 mg/kg 体重 [BW] 的异丙肾上腺素）、ISO + SHC（150 µg/kg BW，口服 7天）和 ISO + 醋硝香豆素（150 µg/kg BW，口服 7 天）。结果表明，ISO 引起心电图 (ECG) 模式的显着改变和血浆心肌肌钙蛋白 T、肌酸激酶-MB、总胆固醇、甘油三酯、低密度脂蛋白胆固醇、乳酸脱氢酶、天冬氨酸转氨酶和丙二醛的增加。此外，ISO 降低高密度脂蛋白胆固醇含量和超氧化物歧化酶和谷胱甘肽过氧化物酶的活性，诱导心肌坏死。然而，SHC 给药显示心脏功能障碍标志物显着下降，恢复正常的心电图模式，以及改善脂质参数。此外，SHC 治疗显着减轻了心脏氧化应激和心肌重构过程。总体而言，SHC 通过抗氧化能力提供了对急性心肌梗塞的良好保护。